Transforming growth factor β (TGFb) is associated with many corneal pathologies, diseases and dystrophies. The function of TGFb in adult corneas cannot be studied using conventional transgenic approach because TGFb1 and TGFb2 deficient transgenic animals suffer multiple inflammatory diseases, severe developmental defects, and death by 3-4 weeks of age. This study tested the hypothesis that selective tissue-targeted gene transfer approaches will permit examination of TGFb gene function in the adult cornea without altering TGFb expression in vital organs
Untargeted and uncontrolled gene delivery is a major cause of gene therapy failure. This study aimed...
The cornea represents an ideal tissue to elucidate the potential of molecular medicine to treat gene...
This paper evaluates the effects of adenoviral vector-mediated glial cell-derived neurotrophic facto...
Successful restoration of vision in human patients with gene therapy affirmed its promise to cure oc...
Transforming growth factor-beta (TGFβ) is a pleiotropic multifunctional cytokine that regulates seve...
Corneal blindness is the third leading cause of blindness worldwide. Gene therapy is an emerging tec...
Purpose: The purpose of this study was to develop and characterize a novel bioluminescence transgeni...
TGFBI-associated corneal dystrophies are autosomal dominant diseases caused by missense mutations in...
We assess studies on vector systems for delivery of transgenes to the cornea that have been publishe...
The cornea is an extensively studied model for genetic approaches due to its accessibility, transpar...
Untargeted and uncontrolled gene delivery is a major cause of gene therapy failure. This study aimed...
Corneal scarring is due to aberrant activity of the transforming growth factor β (TGFβ) signaling pa...
PURPOSE: Despite ubiquitous expression of the keratoepithelin (KE) protein encoded by the transformi...
Gene therapy of the eye has made huge advances in recent years, which led to first clinical trials. ...
Transforming growth factor [beta] (TGFb) is known to cause fibrosis in the cornea following injury a...
Untargeted and uncontrolled gene delivery is a major cause of gene therapy failure. This study aimed...
The cornea represents an ideal tissue to elucidate the potential of molecular medicine to treat gene...
This paper evaluates the effects of adenoviral vector-mediated glial cell-derived neurotrophic facto...
Successful restoration of vision in human patients with gene therapy affirmed its promise to cure oc...
Transforming growth factor-beta (TGFβ) is a pleiotropic multifunctional cytokine that regulates seve...
Corneal blindness is the third leading cause of blindness worldwide. Gene therapy is an emerging tec...
Purpose: The purpose of this study was to develop and characterize a novel bioluminescence transgeni...
TGFBI-associated corneal dystrophies are autosomal dominant diseases caused by missense mutations in...
We assess studies on vector systems for delivery of transgenes to the cornea that have been publishe...
The cornea is an extensively studied model for genetic approaches due to its accessibility, transpar...
Untargeted and uncontrolled gene delivery is a major cause of gene therapy failure. This study aimed...
Corneal scarring is due to aberrant activity of the transforming growth factor β (TGFβ) signaling pa...
PURPOSE: Despite ubiquitous expression of the keratoepithelin (KE) protein encoded by the transformi...
Gene therapy of the eye has made huge advances in recent years, which led to first clinical trials. ...
Transforming growth factor [beta] (TGFb) is known to cause fibrosis in the cornea following injury a...
Untargeted and uncontrolled gene delivery is a major cause of gene therapy failure. This study aimed...
The cornea represents an ideal tissue to elucidate the potential of molecular medicine to treat gene...
This paper evaluates the effects of adenoviral vector-mediated glial cell-derived neurotrophic facto...